

The HA Drug Advisory Committee (DAC), comprising doctors, clinical pharmacologists and pharmacists, systematically appraises new drugs every three months. DAC is supported by expert panels which provide specialist views on the selection of drugs for individual specialties.

Drug Advisory Committee Jan 2020 Meeting Outcome

	Generic name	Brand name	Therapeutic Class	Meeting outcome	Primary reason for rejection ¹
1	Baloxavir	Xofluza	Infections	Rejected	Alternative(s) available in HADF with comparable benefits
2	Benralizumab	Fasenra	Respiratory system	Approved	
3	Blinatumumab	Blincyto	Malignant disease and immunosuppression	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient
4	Cabozantinib	Cabometyx	Malignant disease and immunosuppression	Approved	
5	Dabrafenib / Trametinib	Tafinlar / Mekinist	Malignant disease and immunosuppression	Approved	
6	Daratumumab	Darzalex	Malignant disease and immunosuppression	Pending	Pending further information
7	Dupilumab	Dupixent	Skin	Approved	
8	Erenumab	Aimovig	Central nervous system	Rejected	Insufficient comparative studies versus existing treatment
9	Ibrutinib	Imbruvica	Malignant disease and immunosuppression	Approved	
10	Inotuzumab	Besponsa	Malignant disease and immunosuppression	Pending	Pending further information
11	Insulin degludec / liraglutide	Xultophy FlexTouch	Endocrine system	Pending	Pending further information
12	Ipilimumab / Nivolumab	Yervoy / Opdivo	Malignant disease and immunosuppression	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient
13	Letermovir	Prevymis	Infections	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient
14	Nivolumab	Opdivo	Malignant disease and immunosuppression	Approved	
15	Pembrolizumab	Keytruda	Malignant disease and immunosuppression	Approved	
16	Ponatinib	Iclusig	Malignant disease and immunosuppression	Approved in principle	
17	Radium-223 dichloride	Xofigo	Radiopharmaceuticals	Rejected	Alternative(s) available in HADF with comparable benefits
18	Regorafenib	Stivarga	Malignant disease and immunosuppression	Approved	
19	Sugammadex	Bridion	Anaesthesia	Approved	

	Generic name	Brand name	Therapeutic Class	Meeting outcome	Primary reason for rejection ¹
20	Ticagrelor	Brilinta	Cardiovascular system	Approved	

¹ The evaluation embraces the principles of safety, efficacy and cost-effectiveness and takes into account other relevant factors, including international recommendations and practices, advance in technology, disease state, patient compliance, quality of life, actual experience in the use of drugs as well as views of professionals and patients groups.